Dermira (NASDAQ:DERM) Stock Rating Upgraded by BidaskClub

Dermira (NASDAQ:DERM) was upgraded by stock analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report issued on Tuesday, BidAskClub reports.

DERM has been the topic of a number of other research reports. Evercore ISI restated a “buy” rating on shares of Dermira in a research note on Thursday, December 12th. Leerink Swann cut their target price on Dermira from $23.00 to $15.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Svb Leerink restated an “outperform” rating on shares of Dermira in a research note on Thursday, January 2nd. ValuEngine upgraded Dermira from a “strong sell” rating to a “sell” rating in a research note on Friday, January 10th. Finally, Needham & Company LLC restated a “buy” rating and issued a $20.00 target price on shares of Dermira in a research note on Monday, December 30th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $17.63.

DERM stock traded up $0.04 during trading on Tuesday, hitting $19.19. The company had a trading volume of 844,986 shares, compared to its average volume of 3,048,464. The company has a fifty day moving average price of $13.24 and a two-hundred day moving average price of $9.20. The company has a current ratio of 7.03, a quick ratio of 6.63 and a debt-to-equity ratio of 25.08. The company has a market cap of $1.04 billion, a P/E ratio of -3.66 and a beta of 1.62. Dermira has a fifty-two week low of $5.25 and a fifty-two week high of $19.48.

Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.40) by $0.34. The business had revenue of $11.53 million for the quarter, compared to analyst estimates of $11.07 million. Dermira had a negative return on equity of 583.07% and a negative net margin of 256.08%. On average, analysts expect that Dermira will post -4.15 earnings per share for the current year.

In related news, Director Matthew K. Fust sold 3,000 shares of Dermira stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $12.00, for a total value of $36,000.00. Following the sale, the director now owns 8,051 shares of the company’s stock, valued at approximately $96,612. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 12.40% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Rhumbline Advisers increased its holdings in shares of Dermira by 2.9% in the 3rd quarter. Rhumbline Advisers now owns 56,909 shares of the biopharmaceutical company’s stock valued at $364,000 after acquiring an additional 1,629 shares during the period. California State Teachers Retirement System raised its stake in Dermira by 2.6% in the 3rd quarter. California State Teachers Retirement System now owns 73,649 shares of the biopharmaceutical company’s stock valued at $471,000 after purchasing an additional 1,857 shares during the last quarter. Oppenheimer Asset Management Inc. raised its stake in Dermira by 12.3% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 18,552 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 2,031 shares during the last quarter. Point72 Hong Kong Ltd raised its stake in Dermira by 124.2% in the 2nd quarter. Point72 Hong Kong Ltd now owns 4,170 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 2,310 shares during the last quarter. Finally, Bank of Montreal Can raised its stake in Dermira by 621.8% in the 2nd quarter. Bank of Montreal Can now owns 4,533 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 3,905 shares during the last quarter. 94.49% of the stock is currently owned by institutional investors.

About Dermira

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

Featured Article: Balance Sheet

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.